

Sören Mellstig new President of Gambro

Stockholm, Sweden, June 21, 2000 - Gambro AB (OM Stockholm Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that Sören Mellstig* (48) has been appointed new President and CEO of Gambro. He will take up his new position on July 1 this year. He is succeeding Mikael Lilius, who, as previously has been announced, has been appointed President of the Finnish energy company Fortum.

Sören Mellstig is Executive Vice President of Gambro and responsible for the business area Gambro Renal Products. He joined the company in 1994 and was previously Executive Vice President, Finance and Corporate Control. Earlier he worked with Akzo/Nobel Industries for several years, where he held positions as Director and Controller, Akzo Nobel B.V. and Senior Vice President, Planning and Control, Nobel Industries. Mellstig holds an MBA-degree from Uppsala University, Sweden.

“Sören Mellstig has done an excellent job as head of the business area Gambro Renal Products, which constitutes almost half of the group,” says Claes Dahlbäck, Chairman of Gambro’s Board of Directors. “The change program has been forcefully implemented, profitability is restored and a good base has been established for the future. I am sure that Sören Mellstig will develop and successfully bring Gambro into the future.”

Alain Granger* (58) has been appointed new head of the business area Gambro Renal Products succeeding Sören Mellstig. Alain Granger is a member of the management team of the business area and responsible for Global Marketing as well as Sales in Asia and the Americas. He has been with the company since 1978 and was previously President of the former subsidiary Hospal.

*) Photo on www.gambro.com

For further information please contact:

Claes Dahlbäck, Chairman of the Gambro Board of Directors, Investor, tel. +46-8-614 20 00
Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8-613 65 00,
+46-70-513 65 33

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology (BCT). Gambro is one of the leading providers of kidney dialysis services in the world. Gambro treats about 44,700 patients in 600 clinics worldwide. Renal care products comprise dialyzers, dialysis machines, blood lines and dialysis concentrates. BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 20 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries.

Gambro AB

A public company (publ)
Reg no. 556041-8005
Hamngatan 2, P O Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com